[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pseudo-hypoparathyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pseudo-hypoparathyroidism":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100550281","tunisian-clinical-registry-on-hypoparathyroidism-and-pseudo-hypoparathyroidism-100550281",false,"NCT06445036","Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism","THYPARS","Inclusion Criteria:\n\n* Hypoparathyroidism defined by low serum calcium \\\u003C 2.2 mmol\u002Fl (\\\u003C 88 mg\u002Fl) associated with inadequate PTH (low or normal) and normal creatinine\n\nExclusion Criteria:\n\n* Cervical surgery \\\u003C 6 months.\n* Transient (neonatal, etc.) or functional (dysmagnesemia, etc.) hypoparathyroidism.\n* Other causes of hypocalcemia: vitamin D deficiency, chronic renal failure, etc.\n* Familial hypocalcemia hypercalciuria.\n* Pseudo-pseudo-hypoparathyroidism.","ALL",{"count":18,"type":19},1000,"ESTIMATED","1 Day","OBSERVATIONAL","Observational, multicenter, national, cross-sectional study aiming to describe the epidemiological clinical, biological and therapeutic profile of patients suffering from defect in secretion (hypoparathyroidism) or action (pseudo-hypoparathyroidism) of parathyroid hormone.",[24,25],"Hypoparathyroidism","Pseudo Hypoparathyroidism",[24,25,27,28,29],"Clinical Registry","Endocrinology","Parathyroid gland","NOT_YET_RECRUITING","2025-02-20",{"date":33,"type":34},"2025-02-21","ACTUAL",{"date":36,"type":19},"2025-02-27",{"date":38,"type":19},"2025-07-27",{"name":40,"class":41},"Dacima Consulting","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100565724","institution-of-an-italian-multicenter-database-of-patients-affected-by-hypoparathyroidism-or-pseudohypoparathyroidism-100565724","NCT06645899","Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism","Creation, Management and Analysis of a National Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism","Inclusion Criteria:\n\n* Cohort 1: chronic hypoparathyroidism (all etiological forms)\n* Cohort 2: pseudohypoparathyroidism\n\nExclusion Criteria:\n\n* None",{"count":51,"type":19},600,"10 Years","The goal of this observational study is to create, manage and analyze a multicenter national database of patients affected by hypoparathyroidism or pseudohypoparathyroidism, aimed at collecting and studying anamnestic, diagnostic, genetic, clinical, and therapeutic data in a relatively wide number of patients with these two rare pathologies, in Italy.\n\nThe study will include 41 specialist clinical centers of endocrinology, pediatric endocrinology, pediatrics, and endocrine surgery, located throughout the Italian territory, and to which patients refer from all the 20 regions of Italy.\n\nData will be collected over time, both in retrospective and prospective manners, during the 10-year duration of the study, starting from the recruiting visit (basal visit) and then during each follow-up visits patients will undergo for the control of disease at the recruiting clinical centers.\n\nCollected data will include both the most classic traits of the pathology and the less common ones, with the final goal of refining and deepening medical knowledge in the field of these two clinical conditions affecting parathyroid function and calcium homeostasis, and, thus, to be able to define optimal clinical and therapeutic management of patients, improving their quality of life.\n\nThe main aspects this observational study aims to assess and clarify are:\n\n1. Evaluation of prevalence and incidence of hypoparathyroidism, globally and in its different etiological forms, and of pseudohypoparathyroidism in Italy.\n2. Clinical characterization of different etiological forms of hypoparathyroidism, through both cross-sectional and longitudinal analyses of collected data.\n3. Clinical characterization of pseudohypoparathyroidism, through both cross-sectional and longitudinal analyses of collected data.\n4. Over time collection of data on bone status and bone fragility in patients with hypoparathyroidism and pseudohypoparathyroidism, to evaluate the prevalence and incidence of fragility fractures in these patients, globally and also based on gender, age, and disease etiology.\n5. Over time evaluation of response to pharmacological therapies in patients with hypoparathyroidism and pseudohypoparathyroidism The study will include two independent cohorts of female and male patients of any age, one including patients with chronic hypoparathyroidism of each etiological forms (cohort 1), and one including patients with pseudohypoparathyroidism (cohort 2). The study does not include either any control group\u002Fcomparison group or healthy volunteers.\n\nThe study itself does not involve any medical intervention or drug administration. Pharmacological treatments for which data on response to therapy will be collected in the database, are those administered to patients for the control\u002Ftreatment of hypoparathyroidism or pseudohypoparathyroidism, regardless of their inclusion in this observational study.",[24,25],[24,56,57,58],"Pseudohypoparathyroidism","Database of patients","Retro-prospective clinical data collection","RECRUITING","2025-01-21",{"date":62,"type":34},"2025-01-23",{"date":64,"type":34},"2024-11-04",{"date":66,"type":19},"2034-11-04",{"name":68,"class":41},"F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore",41]